Dr. Raghu Ramachandra is the Associate Director of Exploratory Pharmacology for the at Sanford Burnham Prebys. He is also the Lead Scientist at the ADME/PK core facility at Conrad Prebys Center for Chemical Genomics.
Prior to joining Sanford Burnham Prebys, Raghu was the Executive Director and head of Scientific Operations at Galore Tx Pharmaceuticals Private Limited, a drug discovery startup based in Bangalore India. He led Galore Tx to be a revenue generating biotech while also heading in vitro, in vivo pharmacology, ADME and in vivo DMPK teams in support of several discovery projects spanning oncology, inflammation, and infectious diseases.
Prior to co-founding Galore Tx, he worked with Aurigene Discovery Technologies Limited (a 100% subsidiary of Dr Reddy’s Laboratories, NYSE: RDY) in Bangalore, India where he established several in vivo disease models for evaluating efficacy and safety of small molecules and peptides.
At the Institute, he has established an ADME/PK core facility to complement the small molecule discovery platforms already in existence. He is involved in strategic planning, and in the coordination of effort between the project teams of the Center and its collaborators to execute projects on schedule and on budget.
Raghu received his doctorate degree (Animal and Food Science, 2008) from West Virginia University, Morgantown, West Virginia and postdoctoral training in host-pathogen interactions from City of Hope National Medical Center, Duarte, CA.
Granted Patent
US11497735B2
Conjoint therapies for immunomodulation
Inventors: Pottayil Govindan N. Sasikumar, Muralidhara Ramachandra, Raghuveer K. Ramachandra, Adam S. Lazorchak, Timothy L. Wyant